HBM Healthcare Investments Reports CHF 23 Million Half-Year Profit for 2024/2025

HBM Healthcare Investments AG announced a preliminary half-year profit of CHF 23 million for the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5% to CHF 244.34, while the share price rose by 1.7% to CHF 189.40.

Both private and listed companies contributed equally to the rise in value. Significant transactions included the sale of Yellow Jersey Therapeutics to Johnson & Johnson and a revaluation of Swixx Biopharma. However, negative currency effects impacted the overall performance, reducing it by nearly 5%.

These preliminary figures will be confirmed upon the release of the final half-year report on 21 October 2024. Dr Andreas Wicki is available for further information.